This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
18 Apr 2011

Pfizer’s Oral JAK Trial Meets RA Endpoint

The study met all primary endpoints at the 10 mg BID dose, showing statistically significant changes versus placebo in reducing signs and symptoms.

Pfizer achieved positive results from the ORAL Scan Phase III study of tofacitinib, an investigational oral JAK inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).
 
Patients were randomized to receive tofacitinib 5 or 10 mg BID or placebo added to background MTX. The study met all primary endpoints at the 10 mg BID dose, showing statistically significant changes versus placebo in reducing signs and symptoms of RA, reducing the progression of structural damage at six months, improving physical function at three months, and in reaching DAS28-4 (ESR) <2.6 at six months.

Related News